UK Markets close in 3 hrs 27 mins

Syros Pharmaceuticals, Inc. (0LC7.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.9339+0.0977 (+11.68%)
As of 04:05PM BST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.87
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 30.9339
52-week low 30.9339
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 830.71M
% held by insiders 14.98%
% held by institutions 172.52%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)31 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-435.73%

Management effectiveness

Return on assets (ttm)-31.84%
Return on equity (ttm)-91.69%

Income statement

Revenue (ttm)24.13M
Revenue per share (ttm)0.38
Quarterly revenue growth (yoy)13.30%
Gross profit (ttm)23.49M
EBITDA -102.36M
Net income avi to common (ttm)-97.48M
Diluted EPS (ttm)-1.5740
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)110.26M
Total cash per share (mrq)1.75
Total debt (mrq)64.89M
Total debt/equity (mrq)103.43
Current ratio (mrq)4.22
Book value per share (mrq)1.71

Cash flow statement

Operating cash flow (ttm)-107.57M
Levered free cash flow (ttm)-58.61M